首页> 外文OA文献 >A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients

【2h】

A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients

机译：B细胞淋巴恶性肿瘤患者非清髓性同种异体干细胞移植伴利妥昔单抗II期研究：化学敏感性患者的持久无事件生存期持久

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Sauter Craig S.; Barker Juliet N.; Lechner Lauren; Zheng Junting; Devlin Sean M.; Papadopoulos Esperanza B.; Perales Miguel-Angel; Jakubowski Ann A.; Goldberg Jenna D.; Koehne Guenther; Ceberio Izaskun; Giralt Sergio; Zelenetz Andrew D.; Moskowitz Craig H.; Castro-Malaspina Hugo;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with BCell lymphoid malignancies: Favorably durable event-free survival in chemosensitive patients [J] . SauterC.S., BarkerJ.N., LechnerL., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2014,第3期

机译：II期研究：非清髓性同种异体干细胞移植联合利妥昔单抗治疗B细胞淋巴恶性肿瘤：对化学敏感患者的无事件生存期持久
2. Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG as GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients With Lymphoid Malignancies: A Single Arm Phase II Study [J] . Jie-ling Jiang, Wen-hui Gao, Li-ning Wang, Frontiers in Medicine . 2021,第a期

机译：移植后环磷酰胺，Tacrolimus和低剂量ATG作为GVHD预防成两术外周期干细胞移植成年患者淋巴恶恶性肿瘤：单一ARM期II研究
3. Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up. [J] . Patil S, Spencer A, Schwarer A, Bone marrow transplantation . 2010,第7期

机译：预后较差的髓样和淋巴恶性肿瘤患者，降低强度的条件同种异体造血干细胞移植可实现持久的无病生存和总体生存：80个月的随访。
4. SUPERIOR SURVIVAL IN PRIMARY SYSTEMIC AMYLOIDOSIS PATIENTS UNDERGOING PERIPHERAL BLOOD STEM CELL TRANSPLANT : A CASE CONTROL STUDY [C] . A. Dispenzieri, R.A. Kyle, M.Q. Lacy, International Symposium on Amyloidosis . 2005

机译：初级全身淀粉样蛋白患者的优越存活患者接受外周血干细胞移植：案例对照研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A Phase 2 Study of a Non-myeloablative Allogeneic Stem Cell Transplant with Peri-transplant Rituximab in Patients with B-cell Lymphoid Malignancies: Favorably Durable Event-free Survival in Chemosensitive Patients [O] . Craig S. Sauter, Juliet N. Barker, Lauren Lechner, -1

机译：B细胞淋巴恶性肿瘤患者非清髓性同种异体干细胞移植联合利妥昔单抗的2期研究：对化学敏感的患者有利的持久无事件生存
7. Early Results of a Phase II Study Adding Peri-Transplant Rituximab to Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients (PTS) with High-Risk Fludarabine-Refractory Chronic Lymphocytic Leukemia (Cll) [O] . Sorror M.L., Storer B., Sandmaier B.M., 2012

机译：高风险氟达拉滨难治性慢性淋巴细胞性白血病（Cll）患者（PTS）的非清髓性调节和同种异体造血细胞移植（HCT）的II期研究的早期结果

A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients

著录项

引文网络

相似文献

相关主题

期刊订阅